Table 2.
Laboratory findings in subjects with mutation in NFKB2 gene.
| Lymphocyte B subpopulations | I.1 | I.2 | Normal range |
|---|---|---|---|
| B cells: CD19+ (cells/μL) | 216 | 177 | 100–500 |
| B cells (% of lymphocytes) | 11.4 | 8.2 | 6.0–19.0% |
| Memory B cells: CD19+CD27+ (% of lymphocytes) | 7.11% | 5.26% | 0.56–1.76%∗ |
| Marginal zone B cells: CD19+CD27+IgD+ (% of CD19+) | 50.77% | 52.7% | 7.20–30.80% |
| Class-switched memory B cells: CD19+CD27+IgD-IgM- (% of CD19+) | 10.47% | 9.69% | 6.50–29.20% |
| Activated B cells: CD21lowCD38lowCD19high (% of CD19+) | 13.09% | 16.86% | 1.60–10.00% |
| Total transitional B cells: CD38++IgMhigh (% of CD19+) | 10.85% | 7.35% | 0.60–3.50% |
| Plasmablasts: CD38++IgM-CD21lowCD19low (% of CD19+) | 0.2% | 0.18% | 0.40–3.60% |
| Immunoglobulins | |||
| IgG (g/L) | 6.19 | 6.46 | 7.00–16.00 |
| IgA (g/L) | 1.50 | 1.73 | 0.67–3.67 |
| IgM (g/L) | 0.68 | 1.06 | 0.41–2.30 |
| IgE (IU/mL) | <4.63 | 14.80 | 0.00–100.00 |
| Complement | |||
| C3c (g/L) | 0.90 | 0.98 | 0.75–1.36 |
| C4 (g/L) | 0.14 | 0.16 | 0.13–0.40 |
| Lymphocyte proliferation assay | |||
| Phytohemagglutinin (stimulation index) | 69 | 87 | >10 |
| Anti-T3 antigen antibodies (stimulation index) | 79 | 89 | >10 |
| Pokeweed mitogen (stimulation index) | 74 | 105 | >10 |
An asterix indicates normal values taken from the Freiburg classification (Warnatz et al., 2002), with other normal values taken from the EUROclass trial published by Wehr et al. (2008). Abnormal values are highlighted in bold.